Indeed, IL-22 was described as an autocrine factor of human lung cancer cells contributing to cancer cell survival and resistance to chemotherapy, and its therapeutic effect was showed in an in vivo xenograft model using IL-22-RNAi plasmids [20]. This evidence concerns the gene IL22 and lung carcinoma.